Share Price and Basic Stock Data
Last Updated: October 18, 2025, 7:15 pm
| PEG Ratio | 3.41 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Aarti Pharmalabs Ltd, a player in the pharmaceuticals industry, reported sales of ₹1,945 Cr for the fiscal year ending March 2023, a significant increase from ₹1,200 Cr in the previous year. The company’s quarterly sales exhibited volatility, with a high of ₹531 Cr in September 2022, but a notable decline to ₹440 Cr in September 2023. Despite these fluctuations, the overall trend reflects a growth trajectory, with recent quarterly sales reaching ₹506 Cr by March 2024 and projected to rise to ₹564 Cr by March 2025. The operating profit margin (OPM) showed a steady improvement, rising from 18% in March 2023 to 22% in March 2025, indicating better cost management. However, the company experienced a dip in sales to ₹386 Cr in June 2025, suggesting potential challenges in maintaining consistent revenue growth. As Aarti Pharmalabs navigates the competitive landscape, its ability to leverage its operational strengths while addressing market dynamics will be crucial for sustained revenue expansion.
Profitability and Efficiency Metrics
The profitability of Aarti Pharmalabs is underscored by its net profit of ₹272 Cr for the fiscal year ending March 2025, up from ₹193 Cr in March 2023. The earnings per share (EPS) also reflected this growth, standing at ₹30.05 in March 2025 compared to ₹21.35 in March 2023. The company’s return on equity (ROE) was reported at 14.5%, while the return on capital employed (ROCE) was 17.4%, both of which are competitive figures within the pharmaceutical sector. The interest coverage ratio (ICR) stood at a robust 17.64x, indicating Aarti’s strong capability to meet its interest obligations. Additionally, the cash conversion cycle (CCC) remained stable at 200 days, reflecting efficient working capital management. However, with the OPM fluctuating between 16% and 26% over the past quarters, maintaining profitability will require continuous focus on operational efficiencies and cost control to counteract any adverse market conditions.
Balance Sheet Strength and Financial Ratios
Aarti Pharmalabs’ balance sheet reflects a solid financial position, with total borrowings recorded at ₹413 Cr against reserves of ₹1,945 Cr as of March 2025. The company’s debt-to-equity ratio was reported at 0.19, indicating a low level of leverage, which is favorable for financial stability. The current ratio stood at 2.01, suggesting strong liquidity to cover short-term obligations. Additionally, the price-to-book value (P/BV) ratio was 3.41x, indicating that the market values the company’s shares higher than its book value, which is a positive sign of investor confidence. The asset turnover ratio remained steady at 0.77, highlighting effective utilization of assets for revenue generation. However, the company must remain vigilant about rising expenses, which totaled ₹1,651 Cr in March 2025, to ensure that profitability is not compromised in the long run.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarti Pharmalabs indicates a diverse ownership structure, with promoters holding 43.72% of the shares as of June 2025. Foreign institutional investors (FIIs) accounted for 7.34%, while domestic institutional investors (DIIs) held 7.80%. The public shareholding constituted 41.12%, reflecting a healthy distribution that can promote stability and investor confidence. Notably, the number of shareholders decreased from 2,76,664 in March 2023 to 1,87,039 in June 2025, which could indicate consolidation among investors or a response to market conditions. The declining promoter shareholding from 45.98% in March 2023 to 43.72% in June 2025 may raise questions about long-term commitment; however, the presence of institutional investors could bolster market confidence. Overall, the mix of shareholders suggests a resilient base, but the trends in promoter and institutional holdings warrant close observation.
Outlook, Risks, and Final Insight
If margins sustain their upward trajectory, Aarti Pharmalabs could capitalize on its strong profitability metrics to further enhance shareholder value. However, the company faces risks, including potential fluctuations in raw material costs and regulatory challenges that could impact operational efficiencies. Additionally, maintaining consistent sales growth amidst market volatility remains a critical concern. The liquidity position is strong, but any increase in borrowings may affect financial flexibility. Conversely, if the company successfully navigates these risks and continues to optimize its cost structure while expanding its revenue base, it could solidify its position in the pharmaceutical sector. Aarti Pharmalabs’ ability to adapt to market conditions and leverage its operational strengths will ultimately determine its long-term success and investor appeal.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aarti Pharmalabs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 457 | 531 | 472 | 485 | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 |
| Expenses | 371 | 441 | 385 | 405 | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 |
| Operating Profit | 86 | 90 | 86 | 80 | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 |
| OPM % | 19% | 17% | 18% | 16% | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% |
| Other Income | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 |
| Interest | 4 | 6 | 5 | 6 | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 |
| Depreciation | 14 | 17 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 |
| Profit before tax | 68 | 69 | 65 | 59 | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 |
| Tax % | 24% | 26% | 27% | 27% | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% |
| Net Profit | 52 | 51 | 48 | 43 | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 |
| EPS in Rs | 5.26 | 4.73 | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 |
Last Updated: August 20, 2025, 12:50 am
Below is a detailed analysis of the quarterly data for Aarti Pharmalabs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 386.00 Cr.. The value appears to be declining and may need further review. It has decreased from 564.00 Cr. (Mar 2025) to 386.00 Cr., marking a decrease of 178.00 Cr..
- For Expenses, as of Jun 2025, the value is 293.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 418.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 125.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 146.00 Cr. (Mar 2025) to 93.00 Cr., marking a decrease of 53.00 Cr..
- For OPM %, as of Jun 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 24.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 65.00 Cr.. The value appears to be declining and may need further review. It has decreased from 115.00 Cr. (Mar 2025) to 65.00 Cr., marking a decrease of 50.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 24.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 50.00 Cr.. The value appears to be declining and may need further review. It has decreased from 88.00 Cr. (Mar 2025) to 50.00 Cr., marking a decrease of 38.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.46. The value appears to be declining and may need further review. It has decreased from 9.75 (Mar 2025) to 5.46, marking a decrease of 4.29.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:05 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,946 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,651 | 1,484 |
| Operating Profit | 0 | 207 | 342 | 386 | 464 | 461 |
| OPM % | 17% | 18% | 21% | 22% | 24% | |
| Other Income | 0 | 3 | 2 | 5 | 10 | 10 |
| Interest | 0 | 12 | 21 | 17 | 27 | 29 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 90 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 352 |
| Tax % | 21% | 26% | 28% | 24% | ||
| Net Profit | 0 | 122 | 193 | 217 | 272 | 266 |
| EPS in Rs | 21.35 | 23.93 | 30.05 | 29.40 | ||
| Dividend Payout % | 0% | 9% | 13% | 17% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 58.20% | 12.44% | 25.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -45.76% | 12.91% |
Aarti Pharmalabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: September 10, 2025, 2:52 pm
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 |
| Reserves | -0 | 1,386 | 1,513 | 1,712 | 1,945 |
| Borrowings | 0 | 341 | 215 | 285 | 413 |
| Other Liabilities | 0 | 312 | 470 | 540 | 503 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 |
| CWIP | 0 | 187 | 102 | 137 | 374 |
| Investments | 0 | 32 | 87 | 107 | 77 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 |
Below is a detailed analysis of the balance sheet data for Aarti Pharmalabs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,945.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,712.00 Cr. (Mar 2024) to 1,945.00 Cr., marking an increase of 233.00 Cr..
- For Borrowings, as of Mar 2025, the value is 413.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 285.00 Cr. (Mar 2024) to 413.00 Cr., marking an increase of 128.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 503.00 Cr.. The value appears to be improving (decreasing). It has decreased from 540.00 Cr. (Mar 2024) to 503.00 Cr., marking a decrease of 37.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,906.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,582.00 Cr. (Mar 2024) to 2,906.00 Cr., marking an increase of 324.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,137.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,033.00 Cr. (Mar 2024) to 1,137.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Mar 2025, the value is 374.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Mar 2024) to 374.00 Cr., marking an increase of 237.00 Cr..
- For Investments, as of Mar 2025, the value is 77.00 Cr.. The value appears to be declining and may need further review. It has decreased from 107.00 Cr. (Mar 2024) to 77.00 Cr., marking a decrease of 30.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,319.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,305.00 Cr. (Mar 2024) to 1,319.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,906.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,582.00 Cr. (Mar 2024) to 2,906.00 Cr., marking an increase of 324.00 Cr..
Notably, the Reserves (1,945.00 Cr.) exceed the Borrowings (413.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -134.00 | 127.00 | 101.00 | 51.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 115 | 84 | 102 | 99 | |
| Inventory Days | 272 | 188 | 230 | 190 | |
| Days Payable | 123 | 106 | 135 | 90 | |
| Cash Conversion Cycle | 264 | 166 | 197 | 200 | |
| Working Capital Days | 111 | 94 | 110 | 105 | |
| ROCE % | 19% | 16% | 17% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Flexi Cap Fund | 875,633 | 0.24 | 46.68 | 875,633 | 2025-04-22 17:25:15 | 0% |
| HDFC Multi Cap Fund | 428,834 | 0.19 | 22.86 | 428,834 | 2025-04-22 15:56:51 | 0% |
| Aditya Birla Sun Life Manufacturing Equity Fund | 78,984 | 0.5 | 4.21 | 78,984 | 2025-04-22 15:56:51 | 0% |
| HDFC Large and Mid Cap Fund - Regular Plan | 67,500 | 0.02 | 3.6 | 67,500 | 2025-04-22 15:56:51 | 0% |
| Axis Capital Builder Fund - Series 4 | 58,149 | 0.12 | 1.6 | 58,149 | 2025-04-22 09:59:38 | 0% |
| HSBC Mid Cap Fund - OLD | 50,000 | 0.1 | 1.11 | 50,000 | 2025-04-22 15:56:51 | 0% |
| L&T Focused Equity Fund | 40,001 | 0.1 | 0.98 | 40,001 | 2025-04-22 17:25:15 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 519 | 0.27 | 0.03 | 519 | 2025-04-22 17:25:15 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 10.00 |
| Basic EPS (Rs.) | 30.06 | 23.93 | 21.35 | 13.49 |
| Diluted EPS (Rs.) | 30.04 | 23.93 | 21.35 | 13.49 |
| Cash EPS (Rs.) | 39.64 | 32.01 | 28.25 | 36.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Revenue From Operations / Share (Rs.) | 233.36 | 204.42 | 214.64 | 263.36 |
| PBDIT / Share (Rs.) | 52.35 | 43.14 | 38.00 | 45.97 |
| PBIT / Share (Rs.) | 42.76 | 35.06 | 31.10 | 36.73 |
| PBT / Share (Rs.) | 39.80 | 33.16 | 28.77 | 34.10 |
| Net Profit / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| NP After MI And SOA / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| PBDIT Margin (%) | 22.43 | 21.10 | 17.70 | 17.45 |
| PBIT Margin (%) | 18.32 | 17.14 | 14.48 | 13.94 |
| PBT Margin (%) | 17.05 | 16.21 | 13.40 | 12.94 |
| Net Profit Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| NP After MI And SOA Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| Return on Networth / Equity (%) | 13.68 | 12.34 | 12.41 | 8.81 |
| Return on Capital Employeed (%) | 17.23 | 16.83 | 17.19 | 11.46 |
| Return On Assets (%) | 9.37 | 8.40 | 8.67 | 5.99 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.15 | 0.13 | 0.24 |
| Asset Turnover Ratio (%) | 0.77 | 0.76 | 0.75 | 0.00 |
| Current Ratio (X) | 2.01 | 1.94 | 1.95 | 1.77 |
| Quick Ratio (X) | 1.12 | 1.01 | 0.93 | 0.95 |
| Inventory Turnover Ratio (X) | 3.44 | 1.38 | 1.78 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 11.64 | 8.35 | 10.04 | 2.02 |
| Dividend Payout Ratio (CP) (%) | 8.82 | 6.24 | 7.59 | 1.50 |
| Earning Retention Ratio (%) | 88.36 | 91.65 | 89.96 | 97.98 |
| Cash Earning Retention Ratio (%) | 91.18 | 93.76 | 92.41 | 98.50 |
| Interest Coverage Ratio (X) | 17.64 | 22.71 | 16.36 | 17.52 |
| Interest Coverage Ratio (Post Tax) (X) | 11.13 | 13.60 | 10.19 | 11.22 |
| Enterprise Value (Cr.) | 7172.16 | 4182.27 | 2678.01 | 0.00 |
| EV / Net Operating Revenue (X) | 3.39 | 2.26 | 1.38 | 0.00 |
| EV / EBITDA (X) | 15.12 | 10.70 | 7.78 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| Retention Ratios (%) | 88.35 | 91.64 | 89.95 | 97.97 |
| Price / BV (X) | 3.41 | 2.24 | 1.60 | 0.00 |
| Price / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| EarningsYield | 0.04 | 0.05 | 0.07 | 0.00 |
After reviewing the key financial ratios for Aarti Pharmalabs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 30.04. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.04, marking an increase of 6.11.
- For Cash EPS (Rs.), as of Mar 25, the value is 39.64. This value is within the healthy range. It has increased from 32.01 (Mar 24) to 39.64, marking an increase of 7.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 233.36. It has increased from 204.42 (Mar 24) to 233.36, marking an increase of 28.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 52.35. This value is within the healthy range. It has increased from 43.14 (Mar 24) to 52.35, marking an increase of 9.21.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.76. This value is within the healthy range. It has increased from 35.06 (Mar 24) to 42.76, marking an increase of 7.70.
- For PBT / Share (Rs.), as of Mar 25, the value is 39.80. This value is within the healthy range. It has increased from 33.16 (Mar 24) to 39.80, marking an increase of 6.64.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For PBDIT Margin (%), as of Mar 25, the value is 22.43. This value is within the healthy range. It has increased from 21.10 (Mar 24) to 22.43, marking an increase of 1.33.
- For PBIT Margin (%), as of Mar 25, the value is 18.32. This value is within the healthy range. It has increased from 17.14 (Mar 24) to 18.32, marking an increase of 1.18.
- For PBT Margin (%), as of Mar 25, the value is 17.05. This value is within the healthy range. It has increased from 16.21 (Mar 24) to 17.05, marking an increase of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 12.87. This value exceeds the healthy maximum of 10. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.87. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.68. This value is below the healthy minimum of 15. It has increased from 12.34 (Mar 24) to 13.68, marking an increase of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.23. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 17.23, marking an increase of 0.40.
- For Return On Assets (%), as of Mar 25, the value is 9.37. This value is within the healthy range. It has increased from 8.40 (Mar 24) to 9.37, marking an increase of 0.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.19, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has increased from 0.76 (Mar 24) to 0.77, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.01, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.12, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.44, marking an increase of 2.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.64. This value is below the healthy minimum of 20. It has increased from 8.35 (Mar 24) to 11.64, marking an increase of 3.29.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 6.24 (Mar 24) to 8.82, marking an increase of 2.58.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.36. This value exceeds the healthy maximum of 70. It has decreased from 91.65 (Mar 24) to 88.36, marking a decrease of 3.29.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 93.76 (Mar 24) to 91.18, marking a decrease of 2.58.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.64. This value is within the healthy range. It has decreased from 22.71 (Mar 24) to 17.64, marking a decrease of 5.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.13. This value is within the healthy range. It has decreased from 13.60 (Mar 24) to 11.13, marking a decrease of 2.47.
- For Enterprise Value (Cr.), as of Mar 25, the value is 7,172.16. It has increased from 4,182.27 (Mar 24) to 7,172.16, marking an increase of 2,989.89.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.26 (Mar 24) to 3.39, marking an increase of 1.13.
- For EV / EBITDA (X), as of Mar 25, the value is 15.12. This value exceeds the healthy maximum of 15. It has increased from 10.70 (Mar 24) to 15.12, marking an increase of 4.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 88.35. This value exceeds the healthy maximum of 70. It has decreased from 91.64 (Mar 24) to 88.35, marking a decrease of 3.29.
- For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has increased from 2.24 (Mar 24) to 3.41, marking an increase of 1.17.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Pharmalabs Ltd:
- Net Profit Margin: 12.87%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.23% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.68% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.4 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.87%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No 22/C/1 & 22/C/2, Vapi Gujarat 396195 | investorrelations@aartipharmalabs.com http://www.aartipharmalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant Vallabhaji Gogri | Chairman Emeritus |
| Mr. Rashesh C Gogri | Chairman & Non-Exe.Director |
| Mrs. Hetal Gogri Gala | Vice Chairperson & M.D |
| Mr. Narendra J Salvi | Managing Director |
| Mr. Rajendra V Gogri | Non Executive Director |
| Mr. Parimal H Desai | Non Executive Director |
| Ms. Nehal Garewal | Non Executive Director |
| Mr. Bhavesh R Vora | Independent Director |
| Mrs. Jeenal K Savla | Independent Director |
| Mrs. Rupal A Vora | Independent Director |
| Mr. Vilas Gajanan Gaikar | Independent Director |
| Dr. Vinay G Nayak | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
FAQ
What is the intrinsic value of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd's intrinsic value (as of 18 October 2025) is 729.12 which is 12.58% lower the current market price of 834.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 7,557 Cr. market cap, FY2025-2026 high/low of 972/550, reserves of ₹1,945 Cr, and liabilities of 2,906 Cr.
What is the Market Cap of Aarti Pharmalabs Ltd?
The Market Cap of Aarti Pharmalabs Ltd is 7,557 Cr..
What is the current Stock Price of Aarti Pharmalabs Ltd as on 18 October 2025?
The current stock price of Aarti Pharmalabs Ltd as on 18 October 2025 is 834.
What is the High / Low of Aarti Pharmalabs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Pharmalabs Ltd stocks is 972/550.
What is the Stock P/E of Aarti Pharmalabs Ltd?
The Stock P/E of Aarti Pharmalabs Ltd is 28.4.
What is the Book Value of Aarti Pharmalabs Ltd?
The Book Value of Aarti Pharmalabs Ltd is 220.
What is the Dividend Yield of Aarti Pharmalabs Ltd?
The Dividend Yield of Aarti Pharmalabs Ltd is 0.60 %.
What is the ROCE of Aarti Pharmalabs Ltd?
The ROCE of Aarti Pharmalabs Ltd is 17.4 %.
What is the ROE of Aarti Pharmalabs Ltd?
The ROE of Aarti Pharmalabs Ltd is 14.5 %.
What is the Face Value of Aarti Pharmalabs Ltd?
The Face Value of Aarti Pharmalabs Ltd is 5.00.